Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.
Neurodegener Dis Manag
; 13(1): 23-34, 2023 02.
Article
in En
| MEDLINE
| ID: mdl-36285716
ABSTRACT
Aim:
Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT).Methods:
Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed.Results:
The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits.Conclusion:
This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
Multiple Sclerosis
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Neurodegener Dis Manag
Year:
2023
Document type:
Article
Affiliation country:
United States